{"id":26270,"date":"2019-03-08T08:00:42","date_gmt":"2019-03-08T08:00:42","guid":{"rendered":"https:\/\/www.edrugstore.com\/blog\/?p=26270"},"modified":"2019-03-05T15:56:45","modified_gmt":"2019-03-05T15:56:45","slug":"why-ed-drug-udenafil-wont-be-available-in-the-u-s-anytime-soon","status":"publish","type":"post","link":"https:\/\/www.edrugstore.com\/blog\/erectile-dysfunction\/why-ed-drug-udenafil-wont-be-available-in-the-u-s-anytime-soon\/","title":{"rendered":"Why ED Drug Udenafil Won’t Be Available in the U.S. Anytime Soon"},"content":{"rendered":"

Udenafil, a relatively new erectile dysfunction drug developed by South Korea\u2019s Mezzion Pharma, has thus far failed to win approval in key markets such as the European Union and the United States.\u00a0<\/em><\/p>\n

Don\u2019t expect to see udenafil, a new oral ED drug developed in South Korea, available for sale in the United States within the near future.<\/p>\n

The U.S. Food and Drug Administration rejected Mezzion Pharma\u2019s new drug application for the medication back in 2017 after finding that the drug was being produced in facilities that failed to meet FDA standards.<\/p>\n

The FDA\u2019s rejection triggered the South Korean biotech company to file suit against Dr. Reddy\u2019s Laboratories, which had been contracted by Mezzion to manufacture the drug. In its filing, Mezzion claimed that Indian-based Dr. Reddy\u2019s hid \u201csignificant deficiencies\u201d and misrepresented its compliance with the FDA\u2019s standards for current good manufacturing practice.<\/p>\n

An Alternative to Cialis?<\/h3>\n

Had udenafil won FDA approval, it would have provided an alternative to Cialis (tadalafil). At higher dosage, udenafil has a half-life similar to that of high-strength Cialis. At lower dosage, udenafil might well provide competition for Cialis\u2019s daily medication, currently the only ED drug of its type available in the United States.<\/p>\n

Sold under the brand-name Zydena in some markets, udenafil is currently available only in South Korea, the Philippines, and Russia. It also has thus far failed to win approval of the European Medicines Agency, which is responsible for regulating the prescription drug market in the European Union.<\/p>\n

\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 * * *<\/p>\n

If you\u2019ve found this article helpful and would like to see more of the same, follow our blog<\/a> on a regular basis.<\/p>\n","protected":false},"excerpt":{"rendered":"

Udenafil, a relatively new erectile dysfunction drug developed by South Korea\u2019s Mezzion Pharma, has thus far failed to win approval in key markets such as the European Union and the United States.\u00a0 Don\u2019t expect to see udenafil, a new oral ED drug developed in South Korea, available for sale in the United States within the […]<\/p>\n","protected":false},"author":7,"featured_media":26271,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_autoblog_aioseo_focus_keyphrase":"","_autoblog_aioseo_title":"","_autoblog_aioseo_description":"","footnotes":""},"categories":[20],"tags":[22],"class_list":["post-26270","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-erectile-dysfunction","tag-ed"],"acf":[],"aioseo_notices":[],"aioseo_head":"\n\t\t\n\t\n\t\n\t\n\t\n\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t